title: Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials.
authors.affiliation: 1 Oncological Pulmonary Unit, San Camillo, High Specialization Hospital, Rome, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Passaro
authors.forename: Bruno
authors.initials: B
authors.lastname: Gori
authors.forename: Filippo
authors.initials: F
authors.lastname: de Marinis
keywords: Non-small-cell lung cancer (NSCLC); afatinib; epithelial growth factor receptor (EGFR); tyrosine kinase inhibitor (TKI)